Alternative Proteins Patents: Who Leads, Where the Gaps Are 2026
- Concentrated at the top. The five leading assignees hold 533 of 1,046 records in scope (51.0%), and the ten leading hold 674 (64.4%) — a short list controls most of the claim space.
- Filing peaked in 2018. 109 records published that year against 33 in 2017; the pace has since eased, with 2021's 38 falling to 2024's 23 (-39% over that span).
- Peptide and microbial claims dominate. C07K peptide/protein claims (46.9%) and C12N microorganism/genetic-engineering claims (46.2%) each touch nearly half of all records, far ahead of formulation-side classes.
Filing growth compares 2021 (38 records) with 2024 (23) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 1,046 records in scope (CR5), not by the ranked leaders only.
What the alternative-proteins patent record actually covers
The search set combines two layers: filings that name alternative proteins as food or edible material, and filings that also carry biological-characterisation language — sequence reads, molecular targets, expression levels, biomarkers, ingredient functionality or shelf stability. That pairing pulls in a corpus that reads less like food science and more like applied molecular biology: DNA-binding protein platforms, checkpoint-therapy biomarker work and microbial expression systems sit alongside ingredient functionality claims, because the same underlying protein-engineering and measurement tools serve both therapeutic and food-protein development.
That mix matters for anyone scoping freedom to operate. A large share of the highest-cited records in this set originate in therapeutic antibody and DNA-binding-domain engineering rather than food formulation, which means claim language written for drug discovery can still read onto a food-protein expression or characterisation method if the technical elements line up.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
Publication counts below are drawn from the 1,046 records in scope. Because publication trails filing by roughly 18 months, the final one or two years in the trend chart will keep rising after this cut-off and should not be read as a real decline yet.
A 2018 peak, then a cooling three-year window
Records published climbed from 33 in 2017 to a peak of 109 in 2018. The most recent complete comparison available is 2021 to 2024, where annual counts fell from 38 to 23 — a 39% drop over three years. 2025 and 2026 figures are still filling in and are not comparable to that trend yet.
Peptide and microbial engineering lead technology composition
C07K (peptides and proteins) and C12N (microorganisms and genetic engineering) each appear on close to half of all 1,046 records — 46.9% and 46.2% respectively. A61K medicinal-preparation claims follow at 34.3%, with measurement-oriented classes such as C12Q, G01N and G16B each present on under a fifth of records. Since records can carry multiple IPC classes, these shares add to more than 100% and should be read as claim-space overlap, not a partition of the field.
Shares are the percentage of the 1,046 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Alternative Proteins Patent Landscape with Eureka
This page is one run against one query. Ask Eureka your own question about alternative proteins patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaThe records other filings cite most
Systems and methods for identifying responders and non-responders to immune checkpoint blockade therapy
Techniques for training a statistical model for determining whether a subject is likely to respond to a checkpoint blockade therapy. The techniques include obtaining, for each subject in a plurality of subjects having responders to a checkpoint blockade therapy and non-responders to the therapy, expression data indicating expression levels for a plurality of genes; determining, for the plurality of genes, expression level differences between the responders and the non-responders using the expression data; identifying, using the determined expression level differences, a subset of genes associated with a therapy in the plurality of genes; training, using the expression data, a statistical model.Filed by BostonGene Corporation; representative of the expression-level biomarker claims that recur across this dataset.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20110301073A1 | Novel DNA-binding proteins and uses thereof | 1,216 |
| 2 | US8586526B2 | DNA-binding proteins and uses thereof | 831 |
| 3 | WO2011146121A1 | Novel DNA-binding proteins and uses thereof | 713 |
| 4 | WO2002092780A2 | Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricul… | 575 |
| 5 | US20050124010A1 | Whole cell engineering by mutagenizing a substantial portion of a starting genome combining mutations and opt… | 268 |
| 6 | WO2011123813A2 | Binding fusion proteins, binding fusion protein-drug conjugates, XTEN-drug conjugates and methods of making a… | 267 |
| 7 | US20040077090A1 | Whole cell engineering by mutagenizing a substantial portion of a starting genome, combining mutations, and o… | 191 |
| 8 | US6479258B1 | Non-stochastic generation of genetic vaccines | 170 |
| 9 | WO2002029032A2 | Whole cell engineering by mutagenizing a substantial portion of a starting genome, combining mutations, and o… | 162 |
| 10 | US20160074535A1 | Compositions and methods for the expression of crispr guide RNAS using the h1 promoter | 141 |
Citation counts accumulate over time inside this searched corpus, so older DNA-binding-protein filings lead the table by volume of citation rather than by current filing activity. Treat the ranking as a signal of platform influence, not of what is being filed today.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the filing pattern signals
Three patterns stand out once the records are broken down by assignee, geography and claim type.
A short list controls half the corpus
The five leading assignees account for 533 of 1,046 records in scope, and the ten leading account for 674. That leaves a long tail among the remaining ranked companies, each holding a small slice — the field is not evenly distributed, and a new entrant is filing into a space where a handful of platforms already occupy the core peptide and microbial-engineering claims.
Activity has eased from its 2018 peak
Published records fell from 38 in 2021 to 23 in 2024, continuing a decline from the 2018 peak of 109. Because publication lags filing by around 18 months, 2025 and 2026 counts are still incomplete and should not yet be read as confirming or reversing that direction.
US and Europe anchor the filing map
The United States receives the largest share of filings at 288, ahead of Europe (EPO) at 135 and WIPO/PCT at 128. Australia, Canada and Israel each register meaningfully lower counts, suggesting protection strategy in this field still centres on the US and European markets before wider PCT-driven expansion.
Influence sits with older DNA-binding-domain filings
The most-cited record in this set, on novel DNA-binding proteins, carries 1,216 citations — well ahead of the next-ranked record at 831. Because citation counts accumulate over a searched corpus's lifetime, this favours earlier filings and should be read as a marker of platform influence rather than of what matters most today.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to alternative proteins patent landscape, with the prior art for and against each one.
Leading assignees and where momentum is shifting
The ranking spans 100 companies and research institutions across therapeutic protein engineering, genomic diagnostics and food-protein development. Ownership is heavily skewed toward the leading names, with most of the ranked list holding only a handful of records each.
One assignee holds roughly a fifth of the field
The leading assignee's 208 records dwarf the fifth-place total of 37 and the tenth-place total of 23, underlining just how top-heavy this landscape is. Its portfolio spans the DNA-binding-protein and checkpoint-biomarker platforms that also dominate the most-cited-record table.
A cluster of therapeutic-biotech filers follows the leader
Fifth place sits at 37 records and tenth place at 23 — a meaningful step down from the leader but still well ahead of the long tail. These mid-tier filers overlap heavily with the DNA-binding-domain and biomarker-diagnostics space rather than pure food-protein formulation.
A tight inventor cluster drives the leader's output
Ten co-assignee pairs appear in the dataset, and the strongest pair shares 27 records together, with two further pairs at 24 and 21. This points to a compact, repeat-collaborating inventor team behind a large share of the leading assignee's filings rather than a broad distributed R&D effort.
Momentum has thinned even among top names
Among the assignees tracked for recent-year activity, the most active filed only 2 records in the latest year, with the rest showing none. That drop-off is consistent with the broader post-2018 easing in filing volume, though the most recent years are still incomplete in the underlying data.
| Assignee | Recent year | YoY |
|---|---|---|
| BostonGene Corporation | 2 | — |
| Pronutria Biosciences | 0 | — |
| ZymoGenetics Inc. | 0 | — |
| Delinia Inc. | 0 | — |
| Vor Biopharma Inc. | 0 | — |
| Johns Hopkins University | 0 | — |
| Pronutria Biosciences | 0 | — |
| Sangamo Therapeutics Inc. | 0 | — |
Using this landscape from here
The dataset points to three practical next steps for a team scoping this space.
Check freedom to operate against the leader's core claims
With one assignee holding 208 of 1,046 records and a tight co-filing cluster behind much of that output, any new peptide-engineering or expression-characterisation filing should be checked against that portfolio first.
Explore assignee portfolios in EurekaTreat 2025–2026 filing counts as incomplete
The apparent decline through 2024 is real, but the last one to two years of any patent trend understate true activity because publication lags filing. Re-check the trend once later years finish populating.
Track filing trends in EurekaLook at formulation-side claims, not just protein engineering
Measurement and formulation classes such as G16B, C12Q and shelf-stability-adjacent filings sit well below the peptide and microbial classes in density, suggesting less-crowded claim space for functional-ingredient work.
Map white space in EurekaCommon questions about the alternative-proteins patent landscape
It is highly concentrated at the top. The five leading assignees together hold 533 of the 1,046 records in scope, or 51.0%, and the ten leading assignees hold 674, or 64.4%. Below that top tier, the remaining ranked companies each hold comparatively small numbers of records, so a new entrant is filing into a field where a handful of platforms already occupy the core peptide and microbial-engineering claim space.
Filing peaked in 2018 at 109 published records and has since eased; the most recent complete comparison shows a drop from 38 records in 2021 to 23 in 2024, a 39% decline over that span. Publication lags filing by roughly 18 months, so 2025 and 2026 figures in any dataset will look artificially low and should not yet be read as confirming further decline. A fair read is that activity has cooled from its 2018 high rather than that it is currently collapsing.
Peptide and protein engineering (IPC class C07K) and microorganism/genetic-engineering methods (C12N) each appear on close to half of all 1,046 records in scope, at 46.9% and 34.3% respectively for the next class down, A61K medicinal preparations. Measurement- and bioinformatics-oriented classes such as C12Q, G01N and G16B each sit under 20% of records. Because a single record can carry multiple IPC classes, these figures describe overlapping claim space rather than a clean split of the field.
US20180357361A1, filed by BostonGene Corporation, is a representative example: it covers training a statistical model on gene expression-level differences between responders and non-responders to checkpoint blockade therapy, then using that model to predict response. It illustrates how expression-level and biomarker claim language recurs across this dataset even where the underlying application is therapeutic rather than food-protein specific. Anyone building expression-based characterisation methods for alternative proteins should review claims of this type for overlap.
The data points toward formulation- and measurement-adjacent branches that sit next to the dense peptide and microbial core but carry far fewer dedicated records, including shelf-stability formulation, ingredient-functionality assay methods, and non-therapeutic biomarker panels built for food proteins rather than drug response. These areas use similar underlying molecular tools to the crowded core claims but apply them to different end uses, which is often where claim space remains genuinely open. A proper freedom-to-operate search is still needed before filing, since low record counts do not guarantee no prior art.
Research Alternative Proteins Patent Landscape in depth with Eureka
Go past this page: query the whole alternative proteins patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.